HM-032

HM-032 is a potent, selective, and reversible ATP-competitive dual inhibitor of phosphoinositide 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR). Developed by HUTCHMED (formerly Hutchison MediPharma), it targets all four class I PI3K isoforms (α, β, δ, and γ) as well as mTOR with nanomolar potency. The compound is designed to address tumors with deregulated PI3K/AKT/mTOR signaling, including those with PIK3CA mutations or HER2 amplification. Notably, HM-032 has demonstrated preclinical activity in tumor models harboring K-Ras or Raf mutations, which are typically associated with resistance to tyrosine kinase inhibitors. Its mechanism involves the inhibition of downstream signaling (p-AKT, p-S6, and p-4EBP1) and the induction of apoptosis through the upregulation of the pro-apoptotic protein Bim. Preclinical evaluations in xenograft models of breast cancer, lung cancer, and glioblastoma showed significant tumor growth inhibition and a pharmacokinetic profile suitable for intermittent oral dosing.